Consolidated Statement of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
REVENUES	$ 0	$ 0	$ 0	$ 0
COST AND EXPENSES
Research and Development	68,081	0	93,287	13,867
General and Administrative	494,963	132,975	989,693	459,411
Consulting and Professional Fees	87,367	39,995	473,562	147,998
Rent	16,200	0	43,071	0
Total Costs and Expenses	666,611	172,970	1,599,614	621,276
OPERATING LOSS	(666,611)	(172,970)	(1,599,614)	(621,276)
OTHER INCOME & (EXPENSES)
Interest Income	297	14	848	14
Interest Expense	(11,726)	$ (8,981)	(44,991)	(26,388)
Loss on Settlement of Debt through Equity Issuance	(140,000)		(976,530)	$ (984,730)
Loss on Settlement of Debt through Issuance of Common Shares of Regen biopharma, Inc. below fair value	(937,425)		(9,116,857)
Interest Expense attributable to amortization of discount	(73,387)		(77,419)
Expense Related to issuance of Convertible Debt to Star City	0		(247,500)
Preferred Shares of Regen Biopharma, Inc. issued pursuant to contractual obligations	$ (321)		$ (3,475)
Other Expenses		$ (65,000)		$ (65,000)
Total Other Income & (Expense)	$ (1,162,562)	(73,477)	$ (10,465,924)	(1,075,614)
NET INCOME (LOSS)	(1,829,173)	(246,447)	(12,065,538)	(1,696,890)
NET INCOME (LOSS) before equity in subsidiary losses	(1,829,173)	(246,447)	(12,065,538)	(1,696,890)
NET INCOME (LOSS)	(1,829,173)	(246,447)	(12,065,538)	(1,696,890)
Less: (Net Income)Loss attributable to noncontrolling interest Regen Biopharma, Inc.	1,274,739	63,388	8,486,861	144,927
NET INCOME (LOSS) available to common shareholders	$ (554,434)	$ (183,059)	$ (3,578,677)	$ (1,551,963)
BASIC AND FULLY DILUTED EARNINGS (LOSS)	$ (0.0001)	$ (0.0001)	$ (0.0009)	$ (0.0006)
Weighted average number of shares outstanding	4,160,041,891	2,951,045,145	3,817,242,852	2,819,220,513